Comparative Pharmacology
Head-to-head clinical analysis: HEMANGEOL versus KERLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEMANGEOL versus KERLONE.
HEMANGEOL vs KERLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hemangeol (propranolol hydrochloride) is a non-selective beta-adrenergic receptor antagonist that competitively blocks beta-1 and beta-2 receptors. In infantile hemangioma, the exact mechanism is not fully understood, but proposed actions include vasoconstriction, inhibition of angiogenesis by downregulating VEGF and bFGF, and induction of apoptosis in endothelial cells.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
3 mg/kg/day orally divided into 2 doses for pediatric patients; adult use not indicated
10 mg orally once daily; may increase to 20 mg once daily if needed. Maximum 20 mg/day.
None Documented
None Documented
3-4 hours in infants (0-1 year) and 3.5-4.5 hours in children (1-6 years); clinical context: requires TID dosing to maintain therapeutic effect.
Terminal elimination half-life is 8-12 hours in healthy adults; may extend to 15-20 hours in renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism via UGT1A9 and CYP2C9; <5% excreted unchanged in urine. Biliary/fecal elimination of metabolites; exact % not defined.
Primarily renal excretion of unchanged drug and metabolites (70-80% unchanged; 20-30% as glucuronide or sulfate conjugates). Biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Beta-Blocker
Beta-Blocker